MYD Stock Overview A genetic testing and precision medicine company, develops genetic tests in the United States and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Myriad Genetics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Myriad Genetics Historical stock prices Current Share Price US$12.50 52 Week High US$25.80 52 Week Low US$12.50 Beta 1.87 1 Month Change -12.59% 3 Month Change -48.35% 1 Year Change -32.43% 3 Year Change -47.10% 5 Year Change -51.55% Change since IPO 418.13%
Recent News & Updates Myriad Genetics Elects Mark S. Davis as New Board Member Dec 11
Third quarter 2024 earnings released: US$0.24 loss per share (vs US$0.75 loss in 3Q 2023) Nov 08 Myriad Genetics, Inc. Reports Impairment Charges for the Third Quarter Ended September 30, 2024
New minor risk - Share price stability Nov 04
Myriad Genetics, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 30
Now 22% undervalued after recent price drop Oct 11 See more updates Myriad Genetics Elects Mark S. Davis as New Board Member Dec 11
Third quarter 2024 earnings released: US$0.24 loss per share (vs US$0.75 loss in 3Q 2023) Nov 08 Myriad Genetics, Inc. Reports Impairment Charges for the Third Quarter Ended September 30, 2024
New minor risk - Share price stability Nov 04
Myriad Genetics, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 30
Now 22% undervalued after recent price drop Oct 11
Myriad Genetics, Inc. Provides Earnings Guidance for the Third Quarter 2024 and Reaffirms Earnings Guidance for the Full-Year 2024 Oct 10
Myriad Genetics, Inc. to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference Sep 19
Independent Director recently sold €245k worth of stock Sep 11
Insider recently sold €288k worth of stock Aug 26
Second quarter 2024 earnings released: US$0.41 loss per share (vs US$1.42 loss in 2Q 2023) Aug 07
Myriad Genetics, Inc. Raises Earnings Guidance for the Full Year 2024 Aug 07
Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer, Effective September 3, 2024 Jul 31
Myriad Genetics, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Jul 30
New minor risk - Financial position Jun 30
CEO, President & Director recently sold €5.3m worth of stock May 17
Myriad Genetics, Inc. Reiterates Earnings Guidance for the Full Year 2024 May 09
First quarter 2024 earnings released: US$0.29 loss per share (vs US$0.67 loss in 1Q 2023) May 08
Myriad Genetics, Inc. to Report Q1, 2024 Results on May 07, 2024 May 01
Myriad Genetics, Inc. Updates Revenue Guidance for the Fiscal Year 2024 Mar 01 Myriad Genetics, Inc. Provides Revenue Guidance for the First Quarter 2024
Full year 2023 earnings released: US$3.18 loss per share (vs US$1.39 loss in FY 2022) Feb 28
Myriad Genetics, Inc. to Report Q4, 2023 Results on Feb 27, 2024 Feb 22
Myriad Genetics, Inc. Appoints George Daneker as President and Chief Clinical Officer of Oncology, Effective March 18, 2024 Jan 31
Myriad Genetics, Inc. (NasdaqGS:MYGN) agreed to acquire Select assets of Intermountain Precision Genomics. Jan 19 Myriad Genetics, Inc. Announces Chief Financial Officer Changes Dec 22
Myriad Genetics, Inc. has completed a Follow-on Equity Offering in the amount of $109.999996 million.
New minor risk - Shareholder dilution Nov 10
Myriad Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million. Nov 10 Myriad Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million. Nov 09
Myriad Genetics, Inc. Provides Financial Guidance for 2023 and 2024 Nov 08
Third quarter 2023 earnings released: US$0.75 loss per share (vs US$0.43 loss in 3Q 2022) Nov 07
Myriad Genetics, Inc. Appoints Samraat S. Raha as Chief Operating Officer, Effective as of December 11, 2023 Nov 03
Myriad Genetics Appoints Sam Raha as Chief Operating Officer, Effective December 11, 2023 Nov 02
Myriad Genetics, Inc. to Report Q3, 2023 Results on Nov 06, 2023 Nov 01
Bernstein Litowitz Berger & Grossmann LLP Proposes Settlement of Class Action Involving Persons Who Purchased or Acquired Myriad Genetics, Inc. Common Stock Oct 05
Insufficient new directors Oct 01
Myriad Genetics Announces Enhancements to the Genesight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status Aug 09
Myriad Genetics, Inc. Provides Earnings Guidance for the Year 2023 Aug 04
Second quarter 2023 earnings released: US$1.42 loss per share (vs US$0.17 loss in 2Q 2022) Aug 04
Myriad Genetics, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 29
Myriad Genetics, Inc. Announces Inclusion of Breast Density to Myrisk(R) with Riskscore(R) Breast Cancer Risk Assessment Jul 25
Myriad Genetics, Inc. Appoints Adam Brufsky as Scientific Advisor Jun 01
Myriad Genetics, Inc. Revises Earnings Guidance for the Full Year of 2023 May 05
First quarter 2023 earnings released: US$0.67 loss per share (vs US$0.26 loss in 1Q 2022) May 04
Full year 2022 earnings released: US$1.39 loss per share (vs US$0.35 loss in FY 2021) Mar 02
Myriad Genetics, Inc. Hires Senior Leaders to Advance Commercial Growth Plans Dec 20
Myriad Genetics, Inc. announces Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model Dec 10
High number of new directors Dec 02
Myriad Genetics Announces Urosuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-Driven Medical Information Nov 11
Third quarter 2022 earnings released: US$0.43 loss per share (vs US$0.31 profit in 3Q 2021) Nov 03 Myriad Genetics, Inc. (NasdaqGS:MYGN) acquired Gateway Genomics, LLC for approximately $110 million.
Myriad Genetics, Inc. Elects Paul M. Bisaro as New Board Member Nov 01
High number of new directors Oct 31
Myriad Genetics, Inc. to Report Q3, 2022 Results on Nov 01, 2022 Oct 27
Myriad Genetics Receives Expanded Coverage in Japan for Use of BRACAnalysis® Diagnostic System as a Companion Diagnostic for Lynparza® in Early-Stage Breast Cancer Aug 26
Second quarter 2022 earnings released: US$0.17 loss per share (vs US$0.061 loss in 2Q 2021) Aug 05
Myriad Genetics, Inc. Provides Earnings Guidance for the Year 2022 Aug 05
Myriad Genetics, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Jul 29
Myriad Genetics, Inc. Announces the Resignation of Dennis Langer as Director Jul 01
Myriad Genetics, Inc. Announces Executive Changes Jun 04
Myriad Genetics Showcases Advancements in Precision Medicine with Recent Oncology Portfolio Expansion and New Data Presentations at ASCO 2022 May 27
First quarter 2022 earnings released: US$0.26 loss per share (vs US$0.52 loss in 1Q 2021) May 06 Myriad Genetics, Inc. Provides Earnings Guidance for the Fiscal Year 2022
High number of new directors Apr 27
Myriad Genetics, Inc., Annual General Meeting, Jun 02, 2022 Apr 15
Myriad Genetics, Inc. Settles the Qui Tam Lawsuit with STF, LLC Apr 03
Forecast to breakeven in 2024 Mar 10
Myriad Genetics, Inc. Reiterates Earnings Guidance for the Fiscal Year 2022 Feb 25
Investor sentiment deteriorated over the past week Feb 23
Myriad Genetics, Inc. to Report Q4, 2021 Results on Feb 24, 2022 Feb 17
Myriad Genetics, Inc. Provides Earnings Guidance for the Year 2022 Jan 12
Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Autoimmune’s Vectra Testing Business from Myriad Genetics, Inc. (NasdaqGS:MYGN). Sep 14
Independent Chair of the Board recently sold €529k worth of stock Aug 08
Myriad Genetics, Inc. Reports Goodwill and Long-Lived Asset Impairment Charges for the Second Quarter Ended June 30, 2021 Aug 05
Myriad Genetics, Inc. Launches New Version of its MyRisk Hereditary Cancer Test Aug 04
Q2 Solutions LLC completed the acquisition of Myriad RBM, Inc. from Myriad Genetics, Inc. (NasdaqGS:MYGN). Jul 03
Q2 Solutions LLC signed a definitive agreement to acquire Myriad RBM, Inc. from Myriad Genetics, Inc. (NasdaqGS:MYGN) for approximately $200 million. May 25
Myriad Genetics, Inc. to Share New Data at 2021 Asco Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries May 21
Myriad Genetics, Inc. Not to Provide Financial Guidance for the Quarter Ending June 30, 2021 or Fiscal Year 2021 May 04 Shareholder Returns MYD DE Biotechs DE Market 7D -7.4% -3.5% -2.0% 1Y -32.4% -14.7% 6.9%
See full shareholder returns
Return vs Market: MYD underperformed the German Market which returned 6.9% over the past year.
Price Volatility Is MYD's price volatile compared to industry and market? MYD volatility MYD Average Weekly Movement 7.9% Biotechs Industry Average Movement 6.8% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: MYD's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: MYD's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer.
Show more Myriad Genetics, Inc. Fundamentals Summary How do Myriad Genetics's earnings and revenue compare to its market cap? MYD fundamental statistics Market cap €1.17b Earnings (TTM ) -€111.17m Revenue (TTM ) €789.34m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) MYD income statement (TTM ) Revenue US$823.60m Cost of Revenue US$254.10m Gross Profit US$569.50m Other Expenses US$685.50m Earnings -US$116.00m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.27 Gross Margin 69.15% Net Profit Margin -14.08% Debt/Equity Ratio 5.3%
How did MYD perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 12:18 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Myriad Genetics, Inc. is covered by 43 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jack Meehan Barclays Derek Taller Benchmark Company Michael Ryskin BofA Global Research
Show 40 more analysts 
